FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912310175> ?p ?o ?g. }

• W2912310175 endingPage "4104" @default.
• W2912310175 startingPage "4104" @default.
• W2912310175 abstract "Abstract Introduction Diffuse large B-cell lymphoma (DLBCL) represents the most common neoplastic disorder of B-lymphocytes. Although great progress has been made in the treatment of DLBCL, patients with double BCL2/MYC expression have been reported to be refractory to R-CHOP regimen. In our clincial trial (NCT02753647), we found that chidamide, a histone deacetylase inhibitor, plus R-CHOP elicits favorable outcome, especially for DLBCL patients with double BCL2/MYC expression. Therefore,we set out to investigate the underlying mechanism. Methods Core needle biopsy of tumor samples of DLBCL with double BCL2/MYC expression were transplanted into immunodecient (NOD-SCID) mice to establish patient-derived xenograft (PDX) models. Heterotopic PDX models were maintained by passaging tumor tissues from mouse to mouse. Chidamide and doxorubicin, either alone or in combination, were applied to PDX models with low passage numbers (<10) to preserve the genetic integrity of the parental tumors. The dose and administration schedule were as follows: doxorubicin 0.6mg/kg twice a week, chidamide 12.5mg/kg/day for two weeks. RNA-seq and ATAC-seq were performed to achieve an integrative transcriptomic and epigenomic anlaysis of PDX models on Day 7 and Day 14 of treatment. The study was approved by Shanghai Rui Jin Hospital Review Board and written informed consent were obtained from patients in accordance with the Declaration of Helsinki. Results We observed significant growth inhibition of xenografted tumors treated with chidamide combined with doxorubicin, as compared to those of the single treatment. RNA-seq analysis revealed that chidamide and doxorubicin synergistically regulate a set of genes associated with B-cell differentiation and multiple signaling transduction pathways involved regulation of BCL2 and MYC, including the IL6-JAK-STAT and PI3K-AKT-MTOR pathways. Furthermore, accessible chroamtin region profiling by ATAC-seq indicated that chidamide and doxorubin co-repress distal cis-regulatory elements (i.e. enhancers) associated with lymphocyte development. Conclusions As a histone deaceltylase inhibitor, chidamide is able to synergize with doxorubicin to inhibit the growth of DLBCL expressing high levels of MYC and BCL2 in PDX models. This is, in part, due to remodeling of the landscape of accessible chromatins in lymphoma cells. Our study provides insight into how epigenetic therapeutics can sensitize DLBCL with double BCL2/MYC expression to conventional chemotherapy. Disclosures No relevant conflicts of interest to declare." @default.
• W2912310175 created "2019-02-21" @default.
• W2912310175 creator A5045752884 @default.
• W2912310175 creator A5057644948 @default.
• W2912310175 creator A5060470951 @default.
• W2912310175 date "2018-11-29" @default.
• W2912310175 modified "2023-09-28" @default.
• W2912310175 title "Synergic Effect of Histone Deacetylase Inhibitor Chidamide with Doxorubicin on Diffuse Large B-Cell Lymphoma with Double BCL2/MYC Expression" @default.
• W2912310175 doi "https://doi.org/10.1182/blood-2018-99-114079" @default.
• W2912310175 hasPublicationYear "2018" @default.
• W2912310175 type Work @default.
• W2912310175 sameAs 2912310175 @default.
• W2912310175 citedByCount "0" @default.
• W2912310175 crossrefType "journal-article" @default.
• W2912310175 hasAuthorship W2912310175A5045752884 @default.
• W2912310175 hasAuthorship W2912310175A5057644948 @default.
• W2912310175 hasAuthorship W2912310175A5060470951 @default.
• W2912310175 hasConcept C104317684 @default.
• W2912310175 hasConcept C126322002 @default.
• W2912310175 hasConcept C2776202225 @default.
• W2912310175 hasConcept C2776694085 @default.
• W2912310175 hasConcept C2778305200 @default.
• W2912310175 hasConcept C2778559949 @default.
• W2912310175 hasConcept C2779338263 @default.
• W2912310175 hasConcept C2781021840 @default.
• W2912310175 hasConcept C2781303535 @default.
• W2912310175 hasConcept C2781462825 @default.
• W2912310175 hasConcept C502942594 @default.
• W2912310175 hasConcept C55493867 @default.
• W2912310175 hasConcept C64927066 @default.
• W2912310175 hasConcept C71924100 @default.
• W2912310175 hasConcept C86803240 @default.
• W2912310175 hasConceptScore W2912310175C104317684 @default.
• W2912310175 hasConceptScore W2912310175C126322002 @default.
• W2912310175 hasConceptScore W2912310175C2776202225 @default.
• W2912310175 hasConceptScore W2912310175C2776694085 @default.
• W2912310175 hasConceptScore W2912310175C2778305200 @default.
• W2912310175 hasConceptScore W2912310175C2778559949 @default.
• W2912310175 hasConceptScore W2912310175C2779338263 @default.
• W2912310175 hasConceptScore W2912310175C2781021840 @default.
• W2912310175 hasConceptScore W2912310175C2781303535 @default.
• W2912310175 hasConceptScore W2912310175C2781462825 @default.
• W2912310175 hasConceptScore W2912310175C502942594 @default.
• W2912310175 hasConceptScore W2912310175C55493867 @default.
• W2912310175 hasConceptScore W2912310175C64927066 @default.
• W2912310175 hasConceptScore W2912310175C71924100 @default.
• W2912310175 hasConceptScore W2912310175C86803240 @default.
• W2912310175 hasIssue "Supplement 1" @default.
• W2912310175 hasLocation W29123101751 @default.
• W2912310175 hasOpenAccess W2912310175 @default.
• W2912310175 hasPrimaryLocation W29123101751 @default.
• W2912310175 hasRelatedWork W1968677790 @default.
• W2912310175 hasRelatedWork W2081071935 @default.
• W2912310175 hasRelatedWork W2237088146 @default.
• W2912310175 hasRelatedWork W2512851344 @default.
• W2912310175 hasRelatedWork W2563150706 @default.
• W2912310175 hasRelatedWork W2912310175 @default.
• W2912310175 hasRelatedWork W3019363632 @default.
• W2912310175 hasRelatedWork W3031932575 @default.
• W2912310175 hasRelatedWork W3130084849 @default.
• W2912310175 hasRelatedWork W4221028290 @default.
• W2912310175 hasVolume "132" @default.
• W2912310175 isParatext "false" @default.
• W2912310175 isRetracted "false" @default.
• W2912310175 magId "2912310175" @default.
• W2912310175 workType "article" @default.